Boston, USA-based start-up Normunity, which is working on drugs based on a potentially breakthrough biotechnology, yesterday launched out of stealth with a $65 million Series A funding round.
The company aims to create a new class of medicines, dubbed immune normalizers, that target novel immune-oncology (I-O) mechanisms that free the body’s normal immunity against cancer. Normunity’s new class of agents target previously undiscovered mechanisms of immune disruption in cancer.
The Series A was led by Canaan Ventures and included participation by Sanofi Ventures, Taiho Ventures and Osage University Partners.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze